Shimadzu Corporation (7701.T) fair value

ACCE thesis

Shimadzu makes analytical and measurement instruments, including liquid and gas chromatographs, mass spectrometers, X-ray inspection systems and medical imaging equipment, sold into pharma, academic labs, semiconductors and industrial QC. The moat is installed base and service revenue: once a lab validates a method on a Shimadzu platform, switching costs are high, and the recurring consumables and maintenance stream supports a 44.9% gross margin. Revenue is growing 10.3% and the 10.9% operating margin leaves room for operating leverage if volumes hold. The stock trades at 19.0x trailing and 20.1x forward earnings, so the forward multiple implies earnings are not expected to step up much from here, which makes this worth a closer look mainly for whether the margin expansion case is real. At 12.3% ROE and a 1.24T JPY market cap, with no index membership, it is a mid-cap quality compounder that is under-followed by global institutions, and the question for us is whether the 10.9% operating margin can rise toward the gross margin's headroom.